Advertisement
The introduction of Cefazolin for injection marks the second productlaunch in three months from Sagent's pipeline of more than 200 products. Thelaunch of Cefazolin for injection follows Sagent's December 2007 introductionof the first full-line of latex-free, multi-source prefilled, ready-to-use,6 mg and 12 mg, adenosine syringes in the market. Sagent will begin marketingand shipping Cefazolin immediately.
Advertisement
"The launch of Cefazolin, the first product to emerge from our extensiveanti-infective pipeline, marks further progress toward Sagent's ultimate goalof becoming a leader in the injectables marketplace," said Jeffrey M. Yordon,chief executive officer, founder, and chairman of the board of Sagent. "Thisproduct provides our customers another sourcing option for this importantantibiotic and, as with all Sagent products, offers enhanced labeling intendedto optimize product safety and increase efficiency in the hospital."
About Cefazolin
Cefazolin for injection, USP, is the generic equivalent ofGlaxoSmithKline's ANCEF(R), an antibiotic used to treat bacterial infections.Cefazolin for injection, USP, is indicated for serious infections such asthose of the respiratory, biliary and urinary tracts, skin and skin structureinfections, bone and joint infections, and other infections caused by variousstrains of streptococci. Prophylactic Cefazolin for injection, USP,preoperative, intraopertative and postoperative administration can beeffective in reducing the incidence of certain surgical infections. The mostcommon adverse effects may include mild nausea, diarrhea, oral candidiasis andpain or tenderness at the injection site. Less common adverse effects includevomiting, and rarely, pseudomembranous colitis.
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, founded in 2006, is a privately held specialtypharmaceutical company focused on developing, manufacturing, sourcing andmarketing pharmaceutical products, with a specific emphasis on injectableproducts. Sagent has created a unique, global network of resources, comprisedof rapid development capabilities, sophisticated manufacturing and innovativedrug-delivery technologies, quickly yielding an extensive portfolio ofpharmaceutical products that fulfills the evolving needs of patients. Sagentcurrently has more than 200 products in development.
To Discover Injectables Excellence(TM) and learn more about Sagent, pleasevisit http://www.SagentPharma.com.
SOURCE Sagent Pharmaceuticals, Inc.
